

8. (amended) The crystal of claim 1 wherein the AR-LBD is mammalian.

9. (amended) The crystal of claim 1 wherein the AR-LBD is rat.

10. (amended) The crystal of claim 1 having unit cell dimensions in angstroms: $a = 56.03 \pm 5\%$, $b = 66.27 \pm 5\%$, $c = 70.38 \pm 5\%$ and an orthorhombic space group P212121.

11. (amended) A crystal that comprises a molecular complex of an AR-LBD and an AR-LBD ligand, wherein the AR-LBD has an AR-LBD ligand binding site defined by the structure coordinates of AR-LBD amino acids V685, L700, L701, S702, S703, L704, N705, E706, L707, G708, E709, Q711, A735, I737, Q738, Y739, S740, W741, M742, G743, L744, M745, V746, F747, A748, M749, G750, R752, Y763, F764, A765, L768, F770, M780, M787, I869, L873, H874, F876, T877 and F878 according to Table A.

13. (amended) A crystal that comprises a molecular complex of an AR-LBD and an AR-LBD ligand, wherein the AR-LBD has an AR-LBD ligand binding site defined by the structure coordinates of AR-LBD amino acids N705, Q711, R752, F764 and T877 according to Table A.

18. (amended) A crystal that comprises a molecular complex of an AR-LBD and an AR-LBD ligand, wherein the AR-LBD ligand is in van der Waals contact or hydrogen bonding contact with a ligand binding site of said AR-LBD and wherein said ligand binding site comprises the structure coordinates of AR-LBD amino acids V685, L700, L701, S702, S703, L704, N705, E706, L707, G708, E709, Q711, A735, I737, Q738, Y739, S740, W741, M742, G743, L744, M745, V746, F747, A748, M749, G750, R752, Y763, F764, A765, L768, F770, M780, M787, I869, L873, H874, F876, T877, F878, L880, L881, V889, F891, P892, E893, M894, M895, A896, E897, I898, I899, S900, V901, Q902, V903, P904 or I906 of AR-LBD according to Table A.

Please add the following new claim:

33. (added) A crystal comprising the AR-LBD crystal having the atomic coordinates of atoms 1-1991 shown in Table A.